# EDGAR Filing Document

**Accession Number:** 0001720725
**File Stem:** 0001193125-23-008484
**Filing Date:** 2023-1
**Character Count:** 2917
**Document Hash:** e2f4153eb1a54643cde61f31cab04acc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-008484.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0001193125-23-008484

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230113

**EFFECTIVENESS DATE**: 20230113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oyster Point Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001720725
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 811030955
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39112
- **FILM NUMBER:** 23529535

**BUSINESS ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 106
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** (609) 382-9032

**MAIL ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 106
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 15** 

------

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Commission File Number: 001-39112** 

------

## Oyster Point Pharma, Inc.
**(Exact Name of Registrant as Specified in Its Charter)** 

------

**202 Carnegie Center, Suite 106** 

**Princeton, New Jersey 08540** 

**(609) 382-9032** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One (1)

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, Oyster Point Pharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **OYSTER POINT PHARMA, INC.** | **OYSTER POINT PHARMA, INC.** |
| Date: January 13, 2023 | By: | /s/ Jeffrey Nau |
|  | Name: | Jeffrey Nau, Ph.D., M.M.S. |
|  | Title: | President and Chief Executive Officer |

---